Namilumab - Amgen/Izana Bioscience/Takeda

Drug Profile

Namilumab - Amgen/Izana Bioscience/Takeda

Alternative Names: AMG 203; Amg203; IZN 101; MT-203; MT03

Latest Information Update: 19 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Micromet Inc
  • Developer Izana Bioscience; Takeda Pharmaceuticals International GmbH
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Granulocyte macrophage colony stimulating factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ankylosing spondylitis
  • No development reported Rheumatoid arthritis
  • Discontinued Plaque psoriasis

Most Recent Events

  • 19 Jun 2018 Phase-II clinical trials in Ankylosing spondylitis (Treatment-experienced) in United Kingdom (SC) (EudraCT2018-000176-15)
  • 20 Dec 2017 Izana Bioscience plans a phase II trial in Ankylosing spondylitis
  • 14 Dec 2017 Namilumab licensed to Izana Bioscience worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top